Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over [ID4025]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC